METASTATIC RENAL CELL CARCINOMA

This study tests whether combining two oral drugs, abemaciclib and cabozantinib, is safe and effective for people with advanced clear cell or translocation kidney cancer that has already been treated with immunotherapy. The trial has two phases: first, finding the best dose with …

This study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…

This Phase III trial tests whether giving radiation in three smaller doses (FSRS) works better than a single large dose (SRS) for cancer that has spread to the brain. About 269 adults with lung, breast, melanoma, kidney, or gastrointestinal cancers will be randomly assigned to on…

This phase II trial tests whether adding precise, high-dose radiation (SABR) to the main kidney tumor improves outcomes for people with metastatic kidney cancer that cannot be surgically removed. Participants receive standard immunotherapy drugs (avelumab, axitinib, or cabozantin…

This study looks at whether getting standard immunotherapy in the morning (before 11 am) or afternoon (after 12 pm) changes how well it fights advanced or metastatic solid tumors. Researchers think the body's internal clock (circadian rhythm) might affect immune activity. About 1…

This study tests whether a digital app that tracks symptoms weekly can help doctors better manage side effects in people with advanced kidney cancer taking cabozantinib and nivolumab. About 83 patients will use the app to report how they feel, and doctors can adjust treatment bas…

This study tests a new medicine, PF-08634404, in adults with advanced kidney cancer that has spread. The goal is to see if the drug is safe and can shrink tumors when used alone or with other cancer drugs. About 224 participants who have not had prior treatment for their advanced…

This Phase 2 trial tests whether combining pembrolizumab (an immunotherapy) with aldesleukin (IL-2) can shrink tumors in people with advanced melanoma or kidney cancer that hasn't responded to prior treatments. About 78 adults will receive two cycles of the combo in the hospital,…

This Phase II trial is testing whether a different dosing schedule of the drug cabozantinib can reduce side effects while still controlling cancer growth. It includes people with advanced kidney cancer (clear cell or non-clear cell) and neuroendocrine tumors (including carcinoid)…

This study tests a new drug called zanzalintinib, either alone or with an immunotherapy (nivolumab), in people with advanced kidney cancer that got worse after standard adjuvant therapy. About 70 adults will take part. The goal is to see if the drug shrinks tumors and is safe.

This study tests a daily pill called olaparib in 20 adults with advanced kidney cancer that has spread. To join, your cancer must have a specific gene change (like BAP-1 or BRCA) and you must have already tried at least one other treatment. The goal is to see if olaparib can shri…

This phase 2 study is testing whether a combination of three drugs—sasanlimab, palbociclib, and axitinib—can shrink tumors or slow the growth of advanced kidney cancer. The trial will enroll 25 adults with clear cell or translocation renal cell carcinoma that has spread. Research…

This study combines a special type of radiation (PULSAR) with immunotherapy drugs to treat metastatic cancers in the abdomen and pelvis, including liver, kidney, and bladder cancers. About 103 participants will receive the treatment to see if it is safe and helps control the dise…

This early-phase trial tests a wearable device that creates electric fields (tumor treating fields) combined with either cabozantinib or nab-paclitaxel and atezolizumab in 43 people with advanced solid tumors in the abdomen or chest. The goal is to find the safest dose and see if…

This study tests whether high-dose, precise radiation (stereotactic radiotherapy) can control a few growing kidney cancer spots while the rest of the disease is stable on current medication. About 77 people with metastatic kidney cancer whose tumors are progressing in only a few …

This study tests whether precisely targeted radiation can control kidney cancer that has started growing in a few spots while a patient is on immunotherapy. About 30 adults with metastatic renal cell carcinoma will receive radiation to up to 5 progressing tumors and continue thei…

This phase III trial is testing whether adding surgery to remove the kidney (nephrectomy) to standard immunotherapy drugs helps people with kidney cancer that has spread live longer. About 364 participants will either receive immunotherapy alone or immunotherapy plus surgery. The…

This phase I/II trial tests a radioactive tracer called 64Cu-GRIP B, which targets granzyme B—a substance released by immune cells. By using PET scans, researchers hope to see immune activity in tumors and predict whether immunotherapy will work. The study involves about 91 adult…

This study tests whether folic acid supplements can reduce mucositis (painful sores in the mouth, nose, throat, or other areas) in people with advanced kidney cancer who are on targeted therapy or immunotherapy. About 100 participants will receive either folic acid or a placebo, …

This study tests whether adding cryoablation (a procedure that freezes and kills cancer cells) to standard radiation therapy provides better pain relief for people whose cancer has spread to their bones. About 40 participants with various cancers will be split into two groups: on…

This early-stage study tests a small implantable device that releases tiny amounts of up to 19 different cancer drugs directly into a kidney tumor. The goal is to see if the device is safe and can help predict which drug works best for each patient. About 20 adults with kidney ca…